drugset / Trial / NCT00959218

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

NCT00959218

Phase 3 Completed 240 enrolled Bionorica Research GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

Timeline

Start
2007-06
Primary completion
2010-03
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 15 mg Oral

Indications